Study of the Safety and Efficacy of Roxadustat in the Treatment of Heart Failure With Chronic Kidney Disease and Anemia

Inclusion Criteria: Male or female, aged ≥18 years at the time of consent Weight between 45-160kg Definite diagnosis of heart failure: according to the diagnostic criteria for heart failure in "Chinese Heart Failure Diagnosis and Treatment Guidelines 2018" eGFR <60mL/min/1.73 m^2 by CKD-EPI. Diagnosed anemia: male hemoglobin <130 g/L, non-pregnant female hemoglobin <120 g/L. Provision of signed informed consent prior to any study specific procedures. Exclusion Criteria: Acute or chronic active bleeding 6 months before enrollment. Anemias due to thalassemia, sickle cell anemia, pure red aplastic anemia, hemolytic anemia, ect. Thromboembolism requiring anticoagulation. Severe Infection. Hepatic impairment aspartate transaminase [AST] or alanine transaminase [ALT] >3x the upper limit of normal [ULN]; or total bilirubin >2x ULN at time of enrolment). Severe malnutrition. Women of child-bearing potential who are not willing to use a medically accepted method of contraception that is considered reliable in the judgment of the investigator OR women who have a positive pregnancy test at enrolment or randomization OR women who are breast-feeding. Patients who have received roxadustat treatment or are allergic to roxadustat.